DUBLIN--(BUSINESS WIRE)--The "Global Janus Kinase (JAK) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
Global janus kinase (JAK) inhibitors are drugs that inhibit the abnormal functionality of enzymes in the JAK family such as JAK1, JAK2, JAK3, and TYK2. The inhibition of these enzymes helps interfere with the JAK-STAT signaling pathway, which has been found to play a key role in the development of various autoimmune disorders and cancer indications. The janus kinase (JAK) inhibitors market analysis considers sales from both autoimmune disorder and oncology.
In 2018, the autoimmune disorders segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high proven efficiency of these drugs will play a significant role in the autoimmune disorders segment to maintain its market position.
Also, global janus kinase (JAK) inhibitors market report also looks at factors such as increasing number of awareness campaigns, application in severe chronic indications, support from the growing healthcare insurance industry. However, the availability of alternative therapies, differential drug pricing, strong adverse effects may hamper the growth of the janus kinase (JAK) inhibitors industry over the forecast period.
Global Janus Kinase (JAK) Inhibitors Market: Overview
Application in severe chronic indications
The global JAK inhibitors market is expected to benefit significantly from the rising use of JAK inhibitors to treat various chronic diseases. The high efficacy of JAK inhibitors for the treatment of autoimmune disorders has increased their adoption for the treatment of rheumatoid arthritis, psoriatic arthritis. and ulcerative colitis. Research on the use of JAK inhibitors has shown significant results in the clinical stages, which has created the market potential for the vendors.
Similarly, the unmet need for the treatment of graft-versus-host disease (GVHD) is high as the treatment landscape is dominated by off-label of therapies such as TNF inhibitors and interleukin inhibitors. To address the high unmet need, vendors in the global JAK inhibitors market are developing novel drugs to treat GVHD. Such factors will lead to the expansion of the global janus kinase (JAK) inhibitors market at a CAGR of over 18% during the forecast period.
Special drug designations
One of the major benefits that most JAK inhibitors have is the special drug designations given by regulatory bodies. Many drugs have received designations such as the orphan drug designation from regulatory bodies such as the US FDA and the EMA. The orphan drug designation is given to a drug by the FDA when it is being developed to treat an indication that less than 200.000 people have in the US. Vendors that have received the orphan drug designation for their drug will get certain benefits associated with regulations and taxes. This development is expected to have a positive impact on the overall market growth.
With the presence of a few major players, the global janus kinase (JAK) inhibitors market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading janus kinase (JAK) inhibitors manufacturers, that include Astellas Pharma Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, and Pfizer Inc.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
- Market segmentation by application
- Comparison by application
- Autoimmune disorders - Market size and forecast 2018-2023
- Oncology - Market size and forecast 2018-2023
- Market opportunity by application
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Increasing research grants
- Special drug designations
- Rising number of strategic alliances
PART 12: VENDOR LANDSCAPE
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Astellas Pharma Inc.
- Eli Lilly and Co.
- Incyte Corp.
- Novartis AG
- Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/r/74wuky